This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Millions of Americans are born predisposed to high levels of a cholesterol called lipoprotein(a). Doctors are finally figuring out how to treat it.

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein (a), or lp (a), met its primary endpoint, reducing lp (a) levels by an average of 93.9% over ...

Lowering your “bad” cholesterol might be doing more than just protecting your heart, it could also be safeguarding your brain ...

Though high cholesterol may contribute to the risk of developing Alzheimer’s disease or a related dementia (ADRD), taking a ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

Corporation highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid, EPA, on ...